Axogen, Inc. (AXGN): Price and Financial Metrics

Axogen, Inc. (AXGN): $9.30

-0.28 (-2.92%)

POWR Rating

Component Grades

Momentum

D

Stability

C

Sentiment

Quality

C

Add AXGN to Watchlist
Sign Up

AXGN Price/Volume Stats

Current price $9.30 52-week high $13.66
Prev. close $9.58 52-week low $7.20
Day low $9.27 Volume 85,200
Day high $9.80 Avg. volume 210,076
50-day MA $9.37 Dividend yield N/A
200-day MA $10.02 Market Cap 398.04M

AXGN Stock Price Chart Interactive Chart >

AXGN POWR Grades

  • AXGN scores best on the Sentiment dimension, with a Sentiment rank ahead of 95.83% of US stocks.
  • AXGN's strongest trending metric is Stability; it's been moving down over the last 179 days.
  • AXGN ranks lowest in Momentum; there it ranks in the 15th percentile.

AXGN Stock Summary

  • AXGN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 77.36 -- higher than 73.45% of US-listed equities with positive expected earnings growth.
  • AXGN's went public 33.18 years ago, making it older than 86.11% of listed US stocks we're tracking.
  • For AXGN, its debt to operating expenses ratio is greater than that reported by 32.71% of US equities we're observing.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AXOGEN INC are KRMD, ASPN, SONM, AEYE, and KTOS.
  • Visit AXGN's SEC page to see the company's official filings. To visit the company's web site, go to www.axogeninc.com.

AXGN Valuation Summary

  • AXGN's price/earnings ratio is -16; this is 166.39% lower than that of the median Healthcare stock.
  • Over the past 243 months, AXGN's price/earnings ratio has gone down 15.3.

Below are key valuation metrics over time for AXGN.

Stock Date P/S P/B P/E EV/EBIT
AXGN 2023-05-23 2.7 4.0 -16.0 -18.6
AXGN 2023-05-22 2.7 4.0 -16.1 -18.6
AXGN 2023-05-19 2.8 4.1 -16.2 -18.8
AXGN 2023-05-18 2.7 4.0 -16.1 -18.6
AXGN 2023-05-17 2.7 4.0 -16.1 -18.7
AXGN 2023-05-16 2.7 4.0 -16.1 -18.6

AXGN Growth Metrics

    Its 3 year cash and equivalents growth rate is now at -29.51%.
  • The 4 year net income to common stockholders growth rate now stands at -91.93%.
  • Its 4 year cash and equivalents growth rate is now at 61.67%.
Over the past 67 months, AXGN's revenue has gone up $88,720,148.

The table below shows AXGN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 133.957 -18.942 -28.819
2022-06-30 128.202 -18.629 -31.642
2022-03-31 127.328 -13.636 -31.8
2021-12-31 127.358 -13.405 -26.985
2021-09-30 128.316 -9.054 -27.709
2021-06-30 130.54 -6.06 -22.047

AXGN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AXGN has a Quality Grade of C, ranking ahead of 50.98% of graded US stocks.
  • AXGN's asset turnover comes in at 0.65 -- ranking 58th of 186 Medical Equipment stocks.
  • ADMT, NDRA, and APYX are the stocks whose asset turnover ratios are most correlated with AXGN.

The table below shows AXGN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.650 0.821 -0.111
2021-03-31 0.625 0.816 -0.133
2020-12-31 0.633 0.808 -0.172
2020-09-30 0.651 0.806 -0.219
2020-06-30 0.661 0.808 -0.294
2020-03-31 0.706 0.829 -0.278

AXGN Price Target

For more insight on analysts targets of AXGN, see our AXGN price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $27.00 Average Broker Recommendation 1.43 (Moderate Buy)

Axogen, Inc. (AXGN) Company Bio


AxoGen, Inc. operates as a medical technology company. It offers a portfolio of nerve repair solutions for various surgical peripheral nerve repair needs. The company is based in Alachua, Florida.


AXGN Latest News Stream


Event/Time News Detail
Loading, please wait...

AXGN Latest Social Stream


Loading social stream, please wait...

View Full AXGN Social Stream

Latest AXGN News From Around the Web

Below are the latest news stories about AXOGEN INC that investors may wish to consider to help them evaluate AXGN as an investment opportunity.

Axogen to Participate at Jefferies Healthcare Conference

ALACHUA, Fla. and TAMPA, Fla., May 24, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Karen Zaderej, Chairman, Chief Executive Officer, and President, will participate in a fireside chat at the Jefferies Healthcare Conference in New York, NY, on Wednesday, June 7, 2023 at 8:30 a.m. ET. The webcast can be accessed live through the Investors page at www.axogeninc.com

Yahoo | May 24, 2023

Axogen to Participate at JMP Securities Life Sciences Conference

ALACHUA, Fla. and TAMPA, Fla., May 12, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that Peter Mariani, Executive Vice President & Chief Financial Officer, will participate in a fireside chat at the JMP Securities Life Sciences Conference in New York on Monday, May 15, 2023 at 3:00 p.m. ET. The webcast can be accessed live through the Investors page at www.axogeninc.c

Yahoo | May 12, 2023

AxoGen (AXGN) Reports Q1 Loss, Tops Revenue Estimates

AxoGen (AXGN) delivered earnings and revenue surprises of 33.33% and 2.41%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Yahoo | May 9, 2023

Axogen, Inc. Reports 2023 First Quarter Financial Results

ALACHUA, Fla. and TAMPA, Fla., May 09, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today reported financial results and business highlights for the first quarter ended March 31, 2023. First Quarter Financial Results and Business Highlights Net revenue was $36.7 million, an increase of 18% over the first quarter of 2022.Gross margin was 81.7%, compared to 82.1% in the first quarter o

Yahoo | May 9, 2023

Axogen, Inc. to report first quarter 2023 financial results and host conference call on May 9, 2023

ALACHUA, Fla. and TAMPA, Fla., April 18, 2023 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced that it will report first quarter 2023 financial results on Tuesday, May 9, 2023 before the market opens. Axogen management will host an investment-community conference call and webcast at 8:00 a.m. ET following the release. Investors interested in participating in the conference cal

Yahoo | April 18, 2023

Read More 'AXGN' Stories Here

AXGN Price Returns

1-mo 1.42%
3-mo 22.69%
6-mo -12.51%
1-year 6.29%
3-year -8.55%
5-year -80.86%
YTD -6.81%
2022 6.51%
2021 -47.65%
2020 0.06%
2019 -12.43%
2018 -27.81%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!